Affiliation:
1. Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece
2. Institute of Applied and Computational Mathematics, Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece
Abstract
The scientific basis for demonstrating bioequivalence between two drug products relies on the comparison of their extent and rate of absorption. For the absorption extent, the area under the C-t curve (AUCt) is used without a doubt. For absorption rate, the maximum observed plasma concentration (Cmax) is still suggested by the authorities, despite the numerous concerns. In this study, the concept of average slope (AS) is introduced as a metric to express the absorption rate of drugs. Principal component analysis and random forest models were applied to actual and simulated two × two crossover bioequivalence studies to show that AS expresses the appropriate properties for characterizing absorption rate. Several absorption kinetics (slow, typical, fast) and sampling schemes (sparse, typical, dense) were simulated. The two machine learning algorithms, applied to all these scenarios, proved the desired properties of AS while showing the non-desired performances of other metrics currently used or proposed in the literature. The estimation of AS does not require any assumptions, models, or transformations and is as simple as that of AUCt. A modified version of AS, termed “weighted AS”, is also introduced in order to place emphasis on early time points where the C-t profile describes more clearly the absorption process.
Subject
Fluid Flow and Transfer Processes,Computer Science Applications,Process Chemistry and Technology,General Engineering,Instrumentation,General Materials Science
Reference24 articles.
1. Niazi, S. (2014). Handbook of Bioequivalence Testing (Drugs and the Pharmaceutical Sciences), CRC Press, Taylor & Francis Group. [2nd ed.].
2. Food and Drug Administration (FDA) (2023, January 04). Guidance for Industry. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs-General Considerations. Draft Guidance. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2013, Available online: https://www.fda.gov/media/88254/download.
3. European Medicines Agency (2023, January 04). Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**. London. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf.
4. Bioequivalence: Performance of several measures of extent of absorption;Bois;Pharm. Res.,1994
5. Evaluation of different metrics as indirect measures of rate of drug absorption from extended-release dosage forms at steady-state;Reppas;Pharm. Res.,1995
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献